RTW Investments LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN)

RTW Investments LP raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 19.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,334,308 shares of the company's stock after acquiring an additional 551,979 shares during the quarter. RTW Investments LP owned approximately 4.85% of Arvinas worth $63,919,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ARVN. KBC Group NV lifted its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Arvinas during the fourth quarter valued at $171,000. Teacher Retirement System of Texas raised its stake in Arvinas by 19.0% during the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after purchasing an additional 2,280 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after purchasing an additional 1,367 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Arvinas during the fourth quarter valued at $332,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ARVN shares. Bank of America decreased their price target on shares of Arvinas from $54.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. The Goldman Sachs Group cut their target price on Arvinas from $12.00 to $8.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Citigroup lowered their price target on Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research report on Monday, May 5th. Morgan Stanley dropped their price objective on shares of Arvinas from $12.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, May 9th. Finally, Wells Fargo & Company reduced their target price on shares of Arvinas from $26.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, Arvinas presently has an average rating of "Moderate Buy" and an average price target of $20.92.

Arvinas Trading Up 0.6%

Shares of NASDAQ ARVN traded up $0.04 during mid-day trading on Monday, reaching $6.53. The company had a trading volume of 1,568,031 shares, compared to its average volume of 1,327,229. The business's 50-day moving average is $7.64 and its 200-day moving average is $15.82. The stock has a market cap of $476.63 million, a price-to-earnings ratio of -2.36 and a beta of 2.21. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $37.38.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The firm's revenue was up 646.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.97) EPS. As a group, equities research analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Insider Buying and Selling at Arvinas

In related news, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. The trade was a 2.64% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,230 shares of company stock valued at $769,402. Company insiders own 4.73% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.